PE20030412A1 - Tecnica de transfeccion intensificada - Google Patents

Tecnica de transfeccion intensificada

Info

Publication number
PE20030412A1
PE20030412A1 PE2001000963A PE2001000963A PE20030412A1 PE 20030412 A1 PE20030412 A1 PE 20030412A1 PE 2001000963 A PE2001000963 A PE 2001000963A PE 2001000963 A PE2001000963 A PE 2001000963A PE 20030412 A1 PE20030412 A1 PE 20030412A1
Authority
PE
Peru
Prior art keywords
cells
protein
plasmides
mammal
heterological
Prior art date
Application number
PE2001000963A
Other languages
English (en)
Inventor
Helena Yee
Myung-Sam Cho
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20030412A1 publication Critical patent/PE20030412A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN SISTEMA VECTOR DE EXPRESION GENICA EN CELULAS DE MAMIFERO QUE INCLUYE UNA PLURALIDAD DE PLASMIDOS Y COMPRENDE: a)UN SISTEMA DE MANTENIMIENTO EPISOMAL QUE COMPRENDE UN ELEMENTO oriP Y UN GEN QUE EXPRESA EBNA1 ESTAN EN EL MISMO PLASMIDO O EN PLASMIDOS SEPARADOS Y/O EN LAS CELULAS HUESPED; b)UN FUERTE PROMOTOR/INTENSIFICADOR TAL COMO CMV; c)UN COMPLEJO DE TRANSACTIVACION DE PROTEINAS QUE INCLUYE TANTO EL ELEMENTO TAT (GEN TRANSACTIVADOR) COMO TAR (SECUENCIA DE RESPUESTA TRANSACTIVADORA) QUE SE ENCUENTRAN EN EL MISMO PLASMIDO O EN PLASMIDOS SEPARADOS O EN CELULAS DE EXPRESION, TAMBIEN INCLUYE LA PROTEINA BMLF1, ORIGINADA A PARTIR DEL VIRUS DE EPSTEIN BARR; d)ADN QUE CODIFICA PARA LA PROTEINA HETEROLOGA QUE SE SELECCIONA DE UNA MUTEINA DE IL-2 QUE TIENE UNA SUSTITUCION DE AMINOACIDOS (N88R) IL-2SA E IL-4R; SIENDO LA LINEA CELULAR DE UN PRIMATE, LINEA CELULAR HIBRIDA SOMATICA HUMANA ATCC, CRL-12568 DERIVADA DE FUSIONES CELULARES DE RINON EMBRIONARIO HUMANO 293S Y CELULAS DE ORIGEN DE LINFOMA DE BURKITT P3HR-1 (HBK11), CELULAS 293 QUE EXPRESAN EBNA 1, OBTENIDAS DE INVITROGEN (293EBNA), 293. LAS PROTEINAS HETEROLOGAS EXPRESADAS POR CELULAS DE MAMIFEROS TIENEN HABITUALMENTE CUALIDADES MEJORES O MAS CONVENIENTES PARA CARACTERIZAR LAS PROTEINAS QUE LAS PROTEINAS EXPRESADAS A PARTIR DE CELULAS DE NO MAMIFEROS
PE2001000963A 2000-09-28 2001-10-23 Tecnica de transfeccion intensificada PE20030412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67584700A 2000-09-28 2000-09-28

Publications (1)

Publication Number Publication Date
PE20030412A1 true PE20030412A1 (es) 2003-06-26

Family

ID=24712193

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000963A PE20030412A1 (es) 2000-09-28 2001-10-23 Tecnica de transfeccion intensificada

Country Status (18)

Country Link
EP (1) EP1356069B1 (es)
JP (1) JP5022555B2 (es)
AR (1) AR035495A1 (es)
AU (1) AU2001289075A1 (es)
CA (1) CA2420771C (es)
CO (1) CO5270027A1 (es)
DE (1) DE60119386T2 (es)
DO (1) DOP2001000254A (es)
EC (1) ECSP014147A (es)
ES (1) ES2263652T3 (es)
GT (1) GT200100194A (es)
HN (1) HN2001000215A (es)
MY (1) MY139948A (es)
PE (1) PE20030412A1 (es)
SV (1) SV2002000640A (es)
TW (1) TWI239354B (es)
UY (1) UY26947A1 (es)
WO (1) WO2002027005A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006121995A (ja) * 2004-10-29 2006-05-18 Tokyo Medical & Dental Univ Ｅｂｎａ１変異体
ES2461591T3 (es) 2005-10-28 2014-05-20 F. Hoffmann-La Roche Ag Expresión de proteínas en células de roedor
US8822214B2 (en) 2009-09-15 2014-09-02 Medimmune Limited Cells for transient expression and uses thereof
US9850498B2 (en) 2012-12-11 2017-12-26 Takara Bio Inc. Expression cassette

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
US6150515A (en) * 1996-07-03 2000-11-21 Massachusetts Institute Of Technology Tat-SF: cofactor for stimulation of transcriptional elongation by HIV-1 Tat
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
IT1302403B1 (it) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression

Also Published As

Publication number Publication date
EP1356069B1 (en) 2006-05-03
JP2004509642A (ja) 2004-04-02
WO2002027005A3 (en) 2003-07-31
WO2002027005A2 (en) 2002-04-04
SV2002000640A (es) 2002-10-24
ECSP014147A (es) 2002-05-23
MY139948A (en) 2009-11-30
GT200100194A (es) 2002-05-16
ES2263652T3 (es) 2006-12-16
AR035495A1 (es) 2004-06-02
DOP2001000254A (es) 2002-06-15
AU2001289075A1 (en) 2002-04-08
HN2001000215A (es) 2003-11-11
TWI239354B (en) 2005-09-11
CA2420771C (en) 2010-12-21
DE60119386T2 (de) 2007-04-19
UY26947A1 (es) 2002-04-26
WO2002027005A9 (en) 2003-02-06
CA2420771A1 (en) 2002-04-04
DE60119386D1 (de) 2006-06-08
JP5022555B2 (ja) 2012-09-12
EP1356069A2 (en) 2003-10-29
CO5270027A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
Ciliberto et al. Common and interchangeable elements in the promoters of genes transcribed by RNA polymerase III
US8133733B2 (en) Nonviral vectors for delivering polynucleotides to target tissues
Roth et al. Active late-appearing variable surface antigen genes in Trypanosoma equiperdum are constructed entirely from pseudogenes.
ES2411962T3 (es) Métodos y composiciones para suministrar polinucleótidos
US11674128B2 (en) Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
ES2061996T3 (es) Regiones no esenciales de avipoxvirus.
NO963358D0 (no) Vertsvektor-system til anvendelse i genterapi
WO2020207286A1 (zh) 利用人工构建rna编辑酶进行rna定点编辑及相关应用
Habison et al. Murine gammaherpesvirus 68 LANA acts on terminal repeat DNA to mediate episome persistence
CN111575319B (zh) 一种高效的crispr rnp和供体dna共位介导的基因插入或替换方法及其应用
KR840005745A (ko) B형 간염비루스 유전자를 삽입한 조환 플라스미드, 이 조환 플라스미드로 전환된 효모 및 b형 간염비루스 표면항원의 제조방법
PE20030412A1 (es) Tecnica de transfeccion intensificada
DE69627644T2 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
JP6956995B2 (ja) ゲノム編集方法
HRP20130947T1 (hr) Poboljšani sustav za eksprimiranje ljudskog dugog pentraksina 3 i njegova upotreba
EP0915166B1 (de) DNA-Virus-Vektoren und Verfahren zu ihrer Herstellung
US20200385710A1 (en) Methods for screening variant of target gene
KR100420798B1 (ko) 펩타이드 벡터
ES2300200B1 (es) Transposon hsmar2 y su uso en la generacion de vectores utiles en terapia genica somatica.
US20230109885A1 (en) Methods for screening variant of target gene
Steiner et al. Bovine herpesvirus 5 BICP0 complements the bovine herpesvirus 1 homolog
WO2021061946A2 (en) A promoter specific for non-pigmented ciliary epithelial cells
CA3234642A1 (en) Transposases and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration
FD Application declared void or lapsed